Compare GLOB & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLOB | BIO |
|---|---|---|
| Founded | 2003 | 1952 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 8.2B |
| IPO Year | 2014 | N/A |
| Metric | GLOB | BIO |
|---|---|---|
| Price | $65.70 | $302.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 4 |
| Target Price | $95.71 | ★ $358.50 |
| AVG Volume (30 Days) | ★ 1.1M | 156.8K |
| Earning Date | 02-19-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.19 | N/A |
| Revenue | $2,484,891,000.00 | ★ $2,557,500,000.00 |
| Revenue This Year | $3.37 | $1.62 |
| Revenue Next Year | $1.84 | $2.26 |
| P/E Ratio | $30.31 | ★ N/A |
| Revenue Growth | ★ 5.56 | N/A |
| 52 Week Low | $54.36 | $211.43 |
| 52 Week High | $228.98 | $373.69 |
| Indicator | GLOB | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 47.30 | 43.61 |
| Support Level | $66.10 | $298.78 |
| Resistance Level | $68.45 | $305.62 |
| Average True Range (ATR) | 2.30 | 7.17 |
| MACD | -0.45 | -0.18 |
| Stochastic Oscillator | 1.70 | 31.12 |
Globant is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2003 in Argentina but is currently headquartered in Luxembourg and primarily serves clients in the US and Latin America. Globant's client base is relatively concentrated in the media and entertainment and financial services industries.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.